More about Neobe Therapeutics
Neobe Therapeutics is a biotechnology company based in Cambridge, United Kingdom, established in 2021. The company focuses on developing engineered live biotherapeutics to improve outcomes in cancer immunotherapy. Neobe utilizes synthetic biology to create programmable microbial therapeutics, which are designed to remodel the microenvironment of solid tumors, particularly targeting immune-excluded tumors that typically have low response rates to immunotherapy. The company has two lead products in pre-clinical development aimed at breast and pancreatic cancers, both of which have shown preclinical efficacy. Neobe plans to initiate first-in-human trials in 2027. The leadership team, including CEO Dr. Pedro Correa de Sampaio and co-founder Annelise Soulier, brings extensive experience in cancer biology and bacterial engineering. Neobe is actively seeking partnerships to advance its drug candidates and expand its impact in the healthcare sector focused on cancer treatment.